Sanfetrinem cilexetil

Drug Profile

Sanfetrinem cilexetil

Alternative Names: GV 118819

Latest Information Update: 13 Dec 1999

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antibacterials; Beta-lactams
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 13 Dec 1999 Discontinued-II for Bacterial infections in Italy (PO)
  • 31 Aug 1999 No-Development-Reported for Bacterial infections in Italy (PO)
  • 20 Aug 1998 An animal study has been added in the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top